<DOC>
	<DOC>NCT01213810</DOC>
	<brief_summary>The goal is to demonstrate the immunogenicity and safety of Zostavax® in HIV positive individuals. Study participants are stratified into different patient groups according to their CD4 cell count, viral load and HIV Status. - Trial with medicinal product - Trial with immunomodulatory product / biological</brief_summary>
	<brief_title>Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criteria: All individuals Age &gt;18 years Male, or female with negative urine pregnancy test VZVseropositive (serologically documented) Agree to use a barrier method of birth control (such as a condom) Written informed consent HIV positive individuals on ART (group A1A3) Continuous ART for &gt;3 months before baseline No change of ART regimen within 1 month before baseline HIVRNA (value must be &lt;3 months old )&lt;50 copies/ml at last visit CD4count (value must be &lt;3 months old) &gt; 500 cells/µl for group A1, 350500 cells/µl for group A2 and 250 349 cells/µl for group A3 Participation in the SHCS HIVpositive individuals without ART (group B) HIV1 RNA &gt;1000 copies/ml (&lt;3 months before baseline) CD4cell count &gt;500 cells/µl (&lt;3 months before baseline) Participation in the SHCS Healthy HIVnegative volunteers (group C) Negative HIVscreening test (&lt;3 months before baseline) CD4 cell count &gt;500 cells/µl Exclusion criteria: Common exclusion criteria Contraindications on ethical grounds Involvement in a conflicting (vaccine or investigational drug) clinical trial (except from the participation in the Swiss HIV Cohort Study). Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the subject. Pregnancy or breast feeding. Other clinically relevant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc), Known or suspected noncompliance, drug or alcohol abuse. Specific exclusion criteria Fever &gt; 38.3 °C or acute illness during the last 4 weeks Exposure to chickenpox or shingles within four weeks prior to study entry History of shingles Immunosuppression due to disease (other than HIV) or due to medication within 30 days of study entry (eg corticosteroids) Household contact with known immunodeficiency (e.g. HIVpositive with CD4 &lt;250 cells/µl) Immunoglobulin or blood product treatment within 1 year prior or 2 month after study vaccination Previous allergic reaction to vaccine components (i.e. neomycin or gelatin) Vaccination with a life attenuated vaccine one month prior to study entry History of chickenpox vaccination Treatment with antiherpes drugs 4 weeks before baseline Severe coagulation disorder or oral anticoagulant treatment Laboratory exclusion criteria. Thrombocytopenia &lt; 50x 103/?l Haemoglobin &lt;12 g/dl More than threefold elevation of ALT Creatinine of more than150 µmol/l Glucose &gt;10 mmol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>VZV (Varicella zoster Virus)</keyword>
	<keyword>vaccine</keyword>
	<keyword>T cell</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>